048410 — Hyundai Bioscience Co Cashflow Statement
0.000.00%
Last trade - 00:00
- KR₩791bn
- KR₩785bn
- KR₩9bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 767 | -8,607 | -20,051 | -15,807 | -14,499 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 3,269 | 4,520 | 10,974 | -4,516 | 5,252 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1,330 | 7,811 | 5,835 | 1,997 | 1,804 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 9,179 | 7,502 | -538 | -16,544 | -6,008 |
Capital Expenditures | -13,065 | -25,204 | -3,762 | -1,544 | -588 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -1,631 | -1,626 | -8,597 | 10,061 | 5,765 |
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -14,697 | -26,831 | -12,359 | 8,518 | 5,177 |
Financing Cash Flow Items | -281 | -867 | -210 | -229 | -289 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 7,880 | 32,951 | 2,994 | 1,673 | -58 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 2,393 | 13,660 | -10,026 | -6,456 | -921 |